Loading clinical trials...
Loading clinical trials...
A Phase 1, Randomized, Double-Blind, Comparator-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Immunogenicity of V540B in Healthy Adults.
Conditions
Interventions
GARDASIL®9 (G9)
V540B
Locations
5
United States
Anaheim Clinical Trials ( Site 0002)
Anaheim, California, United States
California Clinical Trials Medical Group managed by PAREXEL ( Site 0008)
Glendale, California, United States
Velocity Clinical Research, Hallandale Beach ( Site 0003)
Hallandale, Florida, United States
Research Centers of America ( Hollywood ) ( Site 0001)
Hollywood, Florida, United States
Velocity Clinical Research, Omaha ( Site 0005)
Omaha, Nebraska, United States
Start Date
November 12, 2024
Primary Completion Date
November 20, 2026
Completion Date
November 20, 2026
Last Updated
August 3, 2025
NCT06290258
NCT07310264
NCT00090662
NCT06716502
NCT07483606
NCT06342713
Lead Sponsor
Merck Sharp & Dohme LLC
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions